acquired
Stage
1
Investors
About
XenoPort was a biopharmaceutical company that developed drugs to treat neurological and other disorders before being acquired by Arbor Pharmaceuticals in 2017.
Explore XenoPort's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.